Express News | Zentalis Pharmaceuticals Shares Are Trading Lower After the Company Announced a CFO Transition
Moomoo 24/7Apr 11 15:37 ET
Zentalis Shares Fall After Chief Financial Officer Resigns
By Colin Kellaher Zentalis Pharmaceuticals shares moved lower Thursday after the clinical-stage biopharmaceutical company's top finance executive resigned. Shares of the New York company were recent
WSJApr 11 11:09 ET
Zentalis Pharmaceuticals Announces Executive Financial Transition
TipRanksApr 11 07:12 ET
Express News | Zentalis Pharmaceuticals Inc - Board Appointed Company's President, Cam Gallagher, as Interim Chief Financial Officer
Moomoo 24/7Apr 11 07:03 ET
Express News | Zentalis Pharmaceuticals Inc - Conducting a Search for a New Chief Financial Officer
Moomoo 24/7Apr 11 07:03 ET
Express News | Zentalis Pharmaceuticals Inc - on April 5, Melissa Epperly Resigned as Chief Financial Officer of Zentalis Pharmaceuticals Effective Immediately
Moomoo 24/7Apr 11 07:02 ET
Zentalis Pharmaceuticals to Present at Upcoming Conferences
TipRanksApr 9 16:43 ET
PLAB, SMTC and WOOF Are Among After Hour Movers
Seeking AlphaMar 28 16:52 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market cap stands at $39.3 million. Sunshine Biopharma (NASDAQ:SBFM) sha
BenzingaMar 28 16:31 ET
FLEX, OCUL and PRPL Are Among After Hour Movers
Seeking AlphaMar 11 16:46 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
GlobeNewswireMar 1 18:00 ET
Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates
TipRanksMar 1 01:04 ET
Zentalis Files Automatic Mixed Securities Shelf
Seeking AlphaFeb 29 17:34 ET
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $46 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $46 price target.
BenzingaFeb 28 12:50 ET
Express News | Zentalis Pharmaceuticals Shares Are Trading Higher After Wedbush Maintained a Neutral Rating on the Stock and Raised Its Price Target From $12 to $15
Moomoo 24/7Feb 28 11:07 ET
Zentalis Pharmaceuticals Price Target Raised to $15.00/Share From $12.00 by Wedbush
Zentalis Pharmaceuticals Price Target Raised to $15.00/Share From $12.00 by Wedbush
Dow JonesFeb 28 08:11 ET
Zentalis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/28/2024 1.97% Wedbush $12 → $15 Maintains Neutral 11/08/2023 -18.42% Wedbush $38 → $12 Downgrades Outpe
BenzingaFeb 28 07:59 ET
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
TipRanksFeb 28 07:47 ET
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
GlobeNewswireFeb 28 07:00 ET
No Data
No Data